North Carolina Construction News staff writer
Fujifilm Diosynth Biotechnologies, a manufacturing organization for biologics, vaccines and therapies, has selected Jacobs to provide engineering, procurement and construction management services for its $1.2 billion expansion of its large-scale cell culture contract manufacturing site in Holly Springs.
The project, which builds on the site’s initial phase that broke ground in 2021, will increase manufacturing capacity with the addition of eight new 20,000-liter-cell culture bioreactors and about 400,000 sq. ft. of manufacturing space.
Phase one is expected to be completed in 2025 and work will continue until 2028.
“This expansion of the project at Holly Springs is testament to the relationship of trust and accountability Jacobs and FUJIFILM Diosynth Biotechnologies have built,” said Jacobs Senior Vice President Koti Vadlamudi. “Together we’ll continue to leverage digital innovation and modular design so that medicines and therapies are delivered with quality, flexibility, speed and consistency—now at an even larger scale.”
The expansion leverages “digital innovation and modular design so that medicines and therapies are delivered with quality, flexibility, speed and consistency — now at an even larger scale,” Koti Vadlamudi, Jacobs senior vice president, said in a news release.
The facility will also be used for drug substance manufacturing, automated fill-finish and assembly, packaging and labeling services for global biopharmaceutical customers, said Kenneth Bilenberg, Fujifilm chief operating officer and executive vice president of operations.
The Holly Springs site will be one of the largest end-to-end cell culture contract manufacturing facilities in North America, according to Fujifilm. The $1.2 billion investment forms part of Fujifilm’s broader $3.2 billion commitment to the site.